Trial Profile
Double blinded, placebo-controlled trial of paliperidone addition in SRI [serotonin reuptake inhibitor]-resistant obsessive-compulsive disorder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2014
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Obsessive-compulsive disorders
- Focus Therapeutic Use
- 01 Jun 2013 Primary endpoint 'Yale-Brown-Obsessive-Compulsive-Scale' has not been met.
- 01 Jun 2013 Results published in the Journal of Clinical Psychiatry.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed.